Date & Time: May 26, 2022 | 11:00 am PT
Presented by: Dr. David Kisor, Manchester University
Sponsored by Agena Bioscience®Watch the Recording
Newly identified biomarkers, and evidence to support their potential pharmacogenomic (PGx) relevance, can help address challenges involved with optimizing personalized drug therapy.
In this webinar, Dr. David Kisor from Manchester University will present the latest evidence supporting newly identified (predictive) biomarkers for pharmacogenomics (PGx) as well as evaluating the relevance of certain existing biomarkers. He will introduce a new resource that will be available for comparing and contrasting Clinical Pharmacogenetic Implementation Consortium (CPIC) and U.S. Food and Drug Administration (FDA) PGx data.
Professor of Pharmaceutical Sciences and Pharmacogenomics and Director of Pharmacogenomics, Manchester University
Dr. David Kisor is a Professor of Pharmaceutical Sciences and Pharmacogenomics and the Director of Pharmacogenomics at Manchester University, in Fort Wayne, IN. He is responsible for directing pharmacogenomics across programs in the College of Pharmacy, Natural and Health Sciences. Dr. Kisor received his PharmD from The Ohio State University, completed a postdoctoral fellowship in therapeutic drug monitoring and pharmacokinetics at Ohio State, and has integrated pharmacogenetics and pharmacogenomics with pharmacokinetic subject matter since 1998. Dr. Kisor is very engaged in pharmacogenomics education, having been involved with the American Association of Colleges of Pharmacy Pharmacogenomics Special Interest Group (AACP PGx SIG) in defining/refining competency statements in genetics/genomics for pharmacists as well as leading the effort to provide the first certification program in PGx in the United States.Watch the Recording